Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) have received a consensus rating of “Moderate Buy” from the twenty ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and fifteen have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $102.72.

A number of brokerages have recently issued reports on NTLA. Wells Fargo & Company dropped their price objective on Intellia Therapeutics from $135.00 to $120.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 4th. EF Hutton Acquisition Co. I started coverage on Intellia Therapeutics in a research note on Tuesday, November 1st. They issued a “buy” rating and a $130.00 price target on the stock. Morgan Stanley dropped their price target on Intellia Therapeutics from $84.00 to $83.00 and set an “overweight” rating on the stock in a research note on Friday, November 4th. Credit Suisse Group dropped their price target on Intellia Therapeutics from $109.00 to $88.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 6th. Finally, SVB Leerink dropped their price target on Intellia Therapeutics from $90.00 to $86.00 and set an “outperform” rating on the stock in a research note on Friday, December 2nd.

Intellia Therapeutics Stock Up 3.9 %

Shares of Intellia Therapeutics stock opened at $37.81 on Wednesday. Intellia Therapeutics has a 12-month low of $32.72 and a 12-month high of $108.00. The stock has a market cap of $2.98 billion, a P/E ratio of -6.44 and a beta of 1.93. The business’s 50 day moving average is $42.94 and its 200-day moving average is $53.73.

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.18). Intellia Therapeutics had a negative return on equity of 47.79% and a negative net margin of 859.92%. The company had revenue of $13.27 million for the quarter, compared to the consensus estimate of $13.60 million. On average, sell-side analysts expect that Intellia Therapeutics will post -6.03 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other news, CFO Glenn Goddard sold 2,427 shares of the stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $37.21, for a total transaction of $90,308.67. Following the sale, the chief financial officer now directly owns 15,404 shares of the company’s stock, valued at approximately $573,182.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CFO Glenn Goddard sold 2,427 shares of the stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $37.21, for a total transaction of $90,308.67. Following the sale, the chief financial officer now directly owns 15,404 shares of the company’s stock, valued at approximately $573,182.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John M. Leonard sold 6,673 shares of the stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $37.21, for a total value of $248,302.33. Following the sale, the chief executive officer now directly owns 766,825 shares in the company, valued at $28,533,558.25. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,608 shares of company stock valued at $431,934. 2.60% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NTLA. Eqis Capital Management Inc. lifted its position in shares of Intellia Therapeutics by 5.1% during the 3rd quarter. Eqis Capital Management Inc. now owns 4,345 shares of the company’s stock worth $243,000 after buying an additional 210 shares during the last quarter. Xponance Inc. lifted its position in shares of Intellia Therapeutics by 5.2% during the 3rd quarter. Xponance Inc. now owns 4,250 shares of the company’s stock worth $238,000 after buying an additional 210 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company’s stock worth $123,000 after buying an additional 220 shares during the last quarter. Amalgamated Bank lifted its position in shares of Intellia Therapeutics by 2.0% during the 3rd quarter. Amalgamated Bank now owns 11,352 shares of the company’s stock worth $635,000 after buying an additional 222 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Intellia Therapeutics by 1.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,777 shares of the company’s stock worth $883,000 after buying an additional 247 shares during the last quarter. 85.61% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.